Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11410
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Iuliano-Burns, Sandra | en |
dc.contributor.author | Ayton, J | en |
dc.contributor.author | Hillam, S | en |
dc.contributor.author | Jones, G | en |
dc.contributor.author | King, K | en |
dc.contributor.author | Macleod, S | en |
dc.contributor.author | Seeman, Ego | en |
dc.date.accessioned | 2015-05-16T01:00:13Z | - |
dc.date.available | 2015-05-16T01:00:13Z | - |
dc.date.issued | 2012-01-04 | en |
dc.identifier.citation | Osteoporosis International : A Journal Established As Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of The Usa 2012; 23(10): 2461-7 | en |
dc.identifier.govdoc | 22215183 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/11410 | en |
dc.description.abstract | Sunlight deprivation results in vitamin D deficiency but serum vitamin D levels can be maintained above 50 nmol/L when supplemented with 50,000 IU at least every alternate month.Antarctic expeditioners are exposed to prolonged sunlight deprivation resulting in vitamin D deficiency. We hypothesised that monthly dosing of 50,000 IU vitamin D (~1,600 IU daily) will increase serum 25-hydroxyvitamin D (25(OH)D), suppress parathyroid hormone (PTH) and improve bone mineral density (BMD), 50,000 IU alternate months (~800 IU daily) will maintain these measures, while a single 50,000 IU dose pre-departure (~1,00 IU daily) will not be protective.This was a randomised double-blind study involving 110 healthy adults: 91 males, mean age 41 years (range 24-65 years) working in Antarctica for up to 12 months, who we administered 50,000 IU vitamin D3 monthly, alternate months or a single dose pre-departure. Serum 25(OH)D, PTH, osteocalcin, CTx and calcium were assessed at baseline, mid- and end of expedition. Proximal femur and lumbar spine BMD were assessed pre- and post-expedition.Baseline 25(OH)D was 59 ± 14 nmol/L. By mid-expedition, 25(OH)D increased by 7 nmol/L in those supplemented monthly (p < 0.05) and remained unchanged in those supplemented in alternate months. In those given a single dose pre-departure, 25(OH)D decreased by 8 nmol/L (p < 0.05) and PTH increased by 27% (p < 0.09). Serum osteocalcin increased by ~22% in all groups but BMD remained unchanged. If serum 25(OH)D was >50 nmol/L at baseline, 25(OH)D was maintained above this level with all regimens. If 25(OH)D was <50 nmol/L at baseline, monthly or alternate month regimens were needed to achieve levels >50 nmol/L, the single pre-departure dose was ineffective.During sunlight deprivation of up to 12 months, serum 25(OH)D levels can be maintained above 50 nmol/L when expeditioners are provided with 50,000 I U at least every alternate month. | en |
dc.language.iso | en | en |
dc.subject.other | Adult | en |
dc.subject.other | Aged | en |
dc.subject.other | Antarctic Regions | en |
dc.subject.other | Calcium.blood | en |
dc.subject.other | Dietary Supplements | en |
dc.subject.other | Double-Blind Method | en |
dc.subject.other | Drug Administration Schedule | en |
dc.subject.other | Expeditions | en |
dc.subject.other | Female | en |
dc.subject.other | Femur.physiopathology | en |
dc.subject.other | Humans | en |
dc.subject.other | Lumbar Vertebrae.physiopathology | en |
dc.subject.other | Male | en |
dc.subject.other | Middle Aged | en |
dc.subject.other | Osteocalcin.blood | en |
dc.subject.other | Parathyroid Hormone.blood | en |
dc.subject.other | Sunlight | en |
dc.subject.other | Vitamin D.administration & dosage.analogs & derivatives.blood.therapeutic use | en |
dc.subject.other | Vitamin D Deficiency.complications.physiopathology.prevention & control | en |
dc.subject.other | Young Adult | en |
dc.title | Skeletal and hormonal responses to vitamin D supplementation during sunlight deprivation in Antarctic expeditioners. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Osteoporosis International | en |
dc.identifier.affiliation | Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia | en |
dc.identifier.doi | 10.1007/s00198-011-1858-9 | en |
dc.description.pages | 2461-2467 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/22215183 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Iuliano-Burns, Sandra | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
crisitem.author.dept | Endocrinology | - |
crisitem.author.dept | Endocrinology | - |
Appears in Collections: | Journal articles |
Files in This Item:
File | Size | Format | |
---|---|---|---|
22215183.pdf | 54.43 kB | Adobe PDF | View/Open |
Page view(s)
36
checked on Nov 25, 2024
Download(s)
108
checked on Nov 25, 2024
Google ScholarTM
Check
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.